Swiss biotech company Actelion has seen its share value dip following concerns over a late-stage drug trial in which 120 out of 740 participants died.
The results of the SERAPHIN phase III trial of macitentan, a drug candidate to treat pulmonary arterial hypertension (PAH), have still to be analysed.
A reported comment by Actelion’s CEO Jean-Paul Clozel that the trial results were “very unlikely” to show that the drug extended life triggered a 9% drop in the company’s share value.
Wednesday, February 15, 2012
Pharmaceutical Field - Actelion rocked by drug trial deaths
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment